ADMA Biologics, Inc. (NASDAQ: ADMA)

This lawsuit is for anyone who acquired securities in ADMA Biologics, Inc. (NASDAQ: ADMA) from August 9, 2024 through March 25, 2026.

The lawsuit alleges that the Company and certain of its executives violated federal law. Specifically, the lawsuit alleges that, throughout the time period mentioned above, the Company misled investors regarding its financial condition. More specifically, the lawsuit alleges that the Company misled investors by stuffing the Company’s channels of distribution to artificially inflate revenue.

On March 24, 2026, Culper Research published a report alleging “Channel Stuffing, an Undisclosed Related Party Distributor, and –3% Real Growth in 2025 vs. +20% Reported.” Among other things, the report stated that “two high-level employees at one of ADMA’s two largest distributors,” had confirmed independently that “starting in 2025, ADMA induced the distributor to stock excess ASCENIV by offering rebates and extended payment terms in order to meet order expectations. Distributors take unwanted product without having to pay for it, ADMA books the revenues, and reports growth that was never there.” On this news, the price of the Company’s stock dropped precipitously on unusually heavy trading volume.

The Law Offices of Howard G. Smith seeks to recover damages on behalf of class members. If you acquired securities in ADMA Biologics, Inc. (NASDAQ: ADMA) from August 9, 2024 through March 25, 2026 you may join the lawsuit by submitting your information online, or you may call the Law Offices of Howard G. Smith and speak to Mr. Smith directly to learn how he can protect your rights.